If the reason for the recent circa 20% slide is this guidance, it sure took its time to manifest. Then again, it looks like almost every company that is not tech/healthcare with astronomical P/E is being sold off gradually since the new FY.
We may retest the sub 4 April lows in the coming days, which should be an excellent opportunity to load up on LYL.
News: LYL Lycopodium Revises Guidance Of NPAT In Order Of $11.5 Mln For FY Ending 30 June, page-2
Add LYL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$12.23 |
Change
-0.030(0.24%) |
Mkt cap ! $486.0M | |||
| Open | High | Low | Value | Volume |
| $12.30 | $12.30 | $12.05 | $528.2K | 43.48K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 2 | $12.13 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $12.23 | 1335 | 2 |
View Market Depth
| Last trade - 16.10pm 02/10/2024 (20 minute delay) ? |
| LYL (ASX) Chart |